Gene-edited xenograft donor animals
Herds of genetically modified pigs, raised in designated-pathogen-free facilities, whose organs can be transplanted into humans.
State of the art
United Therapeutics 10-edit UKidney began the EXPAND trial at NYU Langone (November 2025); eGenesis 69-edit EGEN-2784 got IND clearance (September 2025); best expanded-access graft survival to date is 271 days, and a pig liver supported a patient for 171 days.
- Graft survival measured in months, not years - chronic rejection and thrombotic microangiopathy persist
- Porcine endogenous retrovirus and novel-zoonosis risk requires lifelong recipient surveillance
- Organ growth mismatch and porcine protein incompatibilities (complement, coagulation) are only partly corrected by current edit sets
- Designated-pathogen-free breeding and organ-recovery facilities do not exist at transplant-program scale
Who’s working on it
Its 10-edit UKidney entered the EXPAND trial at NYU Langone in November 2025; it is building designated-pathogen-free herds, including a $110M facility in Stewartville, Minnesota due to operate in 2027, toward thousands of organs a year
- eGenesis ↗Startup
Got FDA IND clearance for the 69-edit EGEN-2784 kidney in September 2025; its expanded-access recipient passed seven months dialysis-free, the longest survival with an engineered porcine organ
- David AyaresResearcherRevivicor, United Therapeutics
Made the original alpha-gal knockout pigs and the multi-edit donor lines used in nearly every US xenotransplant to date
- Robert MontgomeryResearcherNYU Langone Transplant Institute
Performed the first decedent xenokidney transplants (2021) and led the first transplant in the EXPAND clinical trial (November 2025)
- Tatsuo KawaiResearcherMassachusetts General Hospital
Lead transplant surgeon for the eGenesis kidney recipients (2025) and director of MGH's clinical transplant tolerance centre
- Chengdu Zhongke Aoge (Clonorgan)Company
Chinese producer of gene-edited donor pigs aiming at mass supply for domestic hospitals, the main effort outside the US
What to invest in
| Kind | Investment | Scale |
|---|---|---|
| infrastructure | Designated-pathogen-free breeding and organ-recovery facilities sized for thousands of transplants per year | $$$ $100M – $1B |
| research | Head-to-head trials resolving how many edits a durable xenograft actually needs, with multi-year follow-up | $$$ $100M – $1B |
Depends on
Required by
No other capability builds on this directly.